Eric Benevich

Chief Commercial Officer

Eric Benevich was appointed Chief Commercial Officer in May 2015 and is responsible for all aspects of commercial development, marketing, and sales of the Neurocrine Biosciences product portfolio. Mr. Benevich has over 30 years of commercial experience in the pharmaceutical industry and previously served in various positions of increasing responsibility at AstraZeneca, Amgen, Peninsula Pharmaceuticals, and Avanir Pharmaceuticals in the sales and marketing of drugs such as Prilosec®, Epogen®, Enbrel®, and Neudexta®. Mr. Benevich has a BBA in International Business from Washington State University.

Board of Directors


Meet Our People

Our employees are passionate, innovative, and collaborative. Together, we strive to relieve suffering for people with great needs, but few options.

Learn More >


The Impact of TD

Tardive dyskinesia (TD) is estimated to affect approximately 600,000 people in the U.S. Although it can look or feel different from day to day, TD is a chronic condition and symptoms may be persistent.

Learn More >


Q2 2022 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) financial results for the second quarter ended June 30, 2022 and reiterated financial guidance for 2022.

Learn More >